Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies.

This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.

Our mission is to make progress toward racial equity in clinical research

Let's make a difference for Underrepresented Patients

Let’s represent the underrepresented Let’s represent the underrepresented

Advancing Health Equity

At Exelixis, we recognize that many racial and ethnic communities are underrepresented in clinical research. Inclusive clinical trial design improves the quality and equity of treatments for key affected populations. Exelixis is dedicated to identifying, discussing, and implementing solutions that will increase the number of patients from underrepresented populations in all phases of clinical trials supported and sponsored by the company.


Oncology clinical trials in the U.S. do not reflect the diversity in our communities. In recent clinical studies that led to FDA oncology approvals (2008-2018), 76.3% of participants were White, 18.3% of participants were Asian, 6.1% were Hispanic, and 3.1% were Black.1 As a comparison, the U.S. population in 2021 was estimated to be 59.3% White, 6.1% Asian, 18.9% Hispanic, and 13.6% Black.2 Increasing the number of people from diverse backgrounds (e.g., age, race, ethnicity, low income) in clinical trials is key to advancing health equity.3,4

Cancer Clinical Trials Underrepresent
Certain U.S. Populations

Black men 37.4% White men 17.9% 2.2x more likely to die
Black men 37.4% White men 17.9% 2.2x more likely to die Black men 37.4% White men 17.9% 2.2x more likely to die
Increasing representation in clinical trials is a step toward improving equal access to potential treatments and applicability of results to all patients burdened by the disease.4-6


Improving representation among marginalized groups is especially important for men with prostate cancer, a group in which the disparity is evident. Clinical trial enrollment for patients with prostate cancer does not accurately reflect the incidence of prostate cancer by race.1,6

Disproportionate Prostate Cancer
Incidence, Mortality, and Clinical
Trial Enrollment1

Black men 37.4% White men 17.9% 2.2x more likely to die
Black and Hispanic men are underrepresented in prostate cancer clinical trial enrollment relative to the proportion of these populations living with and dying from prostate cancer.1

Worse Mortality for
Black Men

Black men 37.4% White men 17.9% 2.2x more likely to die
Prostate cancer is the second leading cause of cancer-related death in Black men. The disparity in mortality may be due to Black men having less access to high-quality treatment.7


Consider discussing clinical trials with your patients during their next visit.

Research shows that more than half of all cancer patients, regardless of race, will agree to participate in a clinical trial if their healthcare provider offers it to them.5

Consider asking your patients living with mCRPC* if they are interested in learning more about the CONTACT-02 clinical trial.

*Metastatic castration-resistant prostate cancer.

Learn more about this trial at and search for NCT04446117, or contact Exelixis Medical Information at 1-888-393-5494 (toll-free), 1-303-389-1847, or